A novel, robust RP-HPLC method has been developed and validated for the precise quantification of Leniolisib, a newly approved treatment for activated phosphoinositide-3 kinase delta syndrome (PI3Kδ). This method is simple, reliable, sensitive, and reproducible, enabling the determination of Leniolisib using a single chromatographic system without modifications in detection wavelength or mobile phase composition. Separation was carried out on a Waters X-Terra RP-18 column (4.6 x 150 mm, 3.5 µm) with a mobile phase of acetonitrile and 0.1% TEA (pH-2.5, OPA) in a 40:60 ratio, at a flow rate of 1 ml/min. Detection was performed at 222.3 nm using a UV detector, with a total run time of six minutes and an elution time of 3.978 minutes. The method demonstrated excellent linearity (r² = 0.9996), with a relative standard deviation (RSD) below 2% and an average recovery greater than 100%. Validation included assessments of linearity, precision, specificity, accuracy, and robustness, confirming its suitability for the quality control of Leniolisib in bulk and tablet dosage forms. Stability studies were conducted via forced degradation experiments. The percentage of degradation observed under acid, alkali, peroxide, reduction, thermal, photolytic, and hydrolysis conditions was 12.0 %, 13.6 %, 15.7 %, 2.1 %, 1.3%, 10.1 %, and 1.0%, respectively. This validated RP-HPLC method is therefore suitable for the routine quantification of Leniolisib in pharmaceutical operations and analytical laboratories.
Author
(s) Details
Panchumarthy Ravi
Sankar
Department of Pharmaceutical Analysis, Vignan Pharmacy
College, Vadlamudi, Guntur District – 522 213, Andhra Pradesh, India.
Kamma Harsha Sri
Department of Pharmaceutical Analysis, Vignan Pharmacy College, Vadlamudi,
Guntur District – 522 213, Andhra Pradesh, India.
Ch. V. Prasada Rao
Department of Pharmaceutics, Vignan Pharmacy College, Vadlamudi, Guntur
District – 522 213, Andhra Pradesh, India.
Kancharla Pujitha
Saint Louis University, Missouri, USA.
Please see the book here:- https://doi.org/10.9734/bpi/prrat/v10/3310
No comments:
Post a Comment